ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: UICC Honors Center Director’s Efforts To Improve Cancer Control In India

March 13, 1998

New Therapies Could Benefit Patients With Difficult Cancers

June 25, 2010

EORTC Screening, Pharmacology Group Focuses On CNU

January 2, 1987

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003

MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies

December 28, 2012

NCI to Study Vasectomy And Prostate Cancer: DCE Concepts OK’d

July 2, 1993